Methods of producing testosteronan polymers using testosteronan synthase

US9695427B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9695427-B2
Application numberUS-201213981886-A
CountryUS
Kind codeB2
Filing dateJan 31, 2012
Priority dateJan 31, 2011
Publication dateJul 4, 2017
Grant dateJul 4, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Testosteronan, a heparosan analog having the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n , is produced by testosteronan synthase, a single protein that is a dual-action catalyst that utilizes UDP-GlcUA and UDP-GlcNAc to synthesize a polysaccharide having the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n .

First claim

Opening claim text (preview).

What is claimed is: 1. A method of producing a polymer comprising the structure [4-D-glucuronic acid-α1,4-D-N-acetylglucosamine-α1-] n ([-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n ), the method comprising the steps of: culturing a recombinant host cell that produces the polypeptide of SEQ ID NO:1; isolating the polypeptide of SEQ ID NO:1; and contacting the polypeptide of SEQ ID NO:1 with at least one UDP-sugar and a functional acceptor, wherein said UDP-sugar is selected from the group consisting of UDP-glucuronic acid (UDP-GlcUA) and UDP-N-acetyl-glucosamine (UDP-GlcNAc), wherein the functional acceptor is elongated to produce a polymer comprising the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n , and wherein the functional acceptor comprises at least two sugar units, wherein said sugar units are selected from the group consisting of uronic acid, a uronic acid analog which results from a substitution at C2 and/or C3 in uronic acid, hexosamine, and a hexosamine analog which results from a substitution at C2 and/or C6 in hexosamine. 2. The method of claim 1 , wherein the at least one UDP-sugar is provided in a stoichiometric ratio to the functional acceptor such that the polypeptide of SEQ ID NO:1 elongates the functional acceptor to provide a polysaccharide having a desired size distribution such that the polysaccharide is substantially monodisperse in size and has a polydispersity value in a range of from 1.0 to 1.5, and wherein the desired size distribution is obtained by controlling the stoichiometric ratio of UDP-sugar to functional acceptor. 3. The method of claim 1 , wherein the uronic acid is selected from the group consisting of GlcUA, iduronic acid (IdoUA) and GalUA; the hexosamine is selected from the group consisting of GlcNAc, GalNAc, GlcN, and GalN; the uronic acid analog is selected from the group consisting of GlcNAcUA, GlcdiNAcUA, and 2-deoxy-2-fluoro-GlcUA; and the hexosamine analog is selected from the group consisting of GlcN, GlcNAcNAc, GlcN[TFA], GlcNBut, GlcNPro, and 6-F-6-deoxyGlcNAc. 4. The method of claim 1 , wherein the at least one UDP-sugar is radioactive or nuclear magnetic resonance-active. 5. The method of claim 1 , further comprising the step of providing one or more divalent metal ions, wherein the divalent metal ions are selected from the group consisting of manganese, magnesium, cobalt, and nickel ions, and wherein the method is carried out in a buffer having a pH from about 4 to about 9. 6. The method of claim 1 , wherein the functional acceptor further comprises a moiety selected from the group consisting of a fluorescent tag, a radioactive tag, a radioactive therapeutic, an affinity tag, a detection probe, a medicant, a biologically active agent, a therapeutic agent, and combinations thereof. 7. The method of claim 1 , wherein the functional acceptor comprises at least one testosteronan oligosaccharide, testosteronan polysaccharide, testosteronan polymer, heparosan oligosaccharide, heparosan polysaccharide, heparosan polymer, GlcUA-based glycoside, or GlcUA-analog glycoside.

Assignees

Inventors

Classifications

  • UDP-glucose 6-dehydrogenase (1.1.1.22) · CPC title

  • Nucleotidyltransferases (2.7.7) · CPC title

  • UTP-glucose-1-phosphate uridylyltransferase (2.7.7.9), i.e. UDP-glucose-pyrophosphorylase · CPC title

  • acting on CH-OH groups as donors (1.1) · CPC title

  • C12N15/52Primary

    Genes encoding for enzymes or proenzymes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9695427B2 cover?
Testosteronan, a heparosan analog having the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n , is produced by testosteronan synthase, a single protein that is a dual-action catalyst that utilizes UDP-GlcUA and UDP-GlcNAc to synthesize a polysaccharide having the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] n .
Who is the assignee on this patent?
Deangelis Paul L, Otto Nigel J, Univ Oklahoma
What technology area does this patent fall under?
Primary CPC classification C12N15/52. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).